<- Go Home
Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Market Cap
$152.5M
Volume
250.6K
Cash and Equivalents
$28.5M
EBITDA
-$85.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$70.1M
Profit Margin
N/A
52 Week High
$20.56
52 Week Low
$4.64
Dividend
N/A
Price / Book Value
1.03
Price / Earnings
-1.46
Price / Tangible Book Value
1.03
Enterprise Value
-$9.1M
Enterprise Value / EBITDA
0.11
Operating Income
-$85.3M
Return on Equity
54.18%
Return on Assets
-32.91
Cash and Short Term Investments
$163.3M
Debt
$1.6M
Equity
$147.5M
Revenue
N/A
Unlevered FCF
-$37.7M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium